Citations

Clear

381 citation(s) found for "Weiss, A".

Improving Distress and Behaviors for Parents of Adolescents With Chronic Pain Enrolled in an Intensive Interdisciplinary Pain Program
Weiss, Karen , Junghans-Rutelonis, Ashley N. , Harbeck‐Weber, Cynthia , McTate, Emily , Luedtke, Connie A. , Bruce, Barbara K. , HARBECK-WEBER, CYNTHIA, Luedtke, Connie, McTate, Emily , Aaron, Rachel V. , Harbeck‐Weber, Cynthia

Mayo Clinic

The Clinical Journal of Pain | June 15, 2019 | Volume: 35 | Issue: 9 | Pages: 772-779

10.1097/ajp.0000000000000737 | PMID 31205071 Get It

Objectives: Intensive interdisciplinary treatment is emerging as an effective treatment of chronic pain in youth. These programs often include a parental component with the belief that targeting parental distress and responses to a child’s pain will improve outcomes. However, few studies have evaluated the impact of a parental intervention in the interdisciplinary treatment of pediatric chronic pain. The present study consists of a nonrandomized pre-post design to evaluate change in psychological and behavioral functioning of parents who participated in intensive parent programming that utilized cognitive-behavioral therapy and acceptance and commitment therapy, delivered within the context of an interdisciplinary intensive 3-week pain treatment program for youth with chronic pain. Materials and Methods: Two hundred twelve parents and their children participated in the study, with 116 participants completing 3-month follow-up measures. Parents completed measures of depressive symptoms, pain catastrophizing, protective responses, and psychological flexibility at admission, discharge, and 3 months after the program. Child functional disability was assessed at the same time points. We examined change in parent factors over time, while controlling for change in child distress. Results: Parents reported significant improvements in all areas of functioning from admission to discharge and improvements were maintained at 3-month follow-up. Discussion: This study provides evidence suggesting parent interventions can be effective in reducing parent distress and behaviors known to be associated with child outcomes.
Functional control of electrophysiological network architecture using direct neurostimulation in humans
Khambhati, Ankit N. , Costantini, Julia , Ezzyat, Youssef , Solomon, Ethan A. , Jobst, Barbara C. , Sheth, Sameer A. , Seger, Sarah , Weiss, Shennan A. , Sperling, Michael R. , Gorniak, Richard , Rizzuto, Daniel S. , Kahana, Michael J. , Lucas, Timothy H., Bassett, Danielle S. , Sperling, Michael R , Weiss, Shennan A , Kahn, Ari E. , Gross, Robert E. , Zaghloul, Kareem A. , Worrell, Gregory A. , Lega, Bradley Charles , Das, Sandhitsu R. , Stein, Joel M. , Davis, Kathryn A. , Tracy, Joseph I. , Jobst, Barbara

Mayo Clinic

Network Neuroscience | May 28, 2019 | Volume: 3 | Issue: 3 | Pages: 848-877

10.1162/netn_a_00089 | PMID 31410383 Get It

Chronically implantable neurostimulation devices are becoming a clinically viable option for treating patients with neurological disease and psychiatric disorders. Neurostimulation offers the ability to probe and manipulate distributed networks of interacting brain areas in dysfunctional circuits. Here, we use tools from network control theory to examine the dynamic reconfiguration of functionally interacting neuronal ensembles during targeted neurostimulation of cortical and subcortical brain structures. By integrating multimodal intracranial recordings and diffusion-weighted imaging from patients with drug-resistant epilepsy, we test hypothesized structural and functional rules that predict altered patterns of synchronized local field potentials. We demonstrate the ability to predictably reconfigure functional interactions depending on stimulation strength and location. Stimulation of areas with structurally weak connections largely modulates the functional hubness of downstream areas and concurrently propels the brain towards more difficult-to-reach dynamical states. By using focal perturbations to bridge large-scale structure, function, and markers of behavior, our findings suggest that stimulation may be tuned to influence different scales of network interactions driving cognition.
Changes in Vedolizumab Utilization Across US Academic Centers and Community Practice Are Associated With Improved Effectiveness and Disease Outcomes
Koliani‐Pace, Jenna L., Singh, Siddharth , Luo, Michelle , Hirten, Robert , Kochhar, Gursimran , Chang, Shannon, Lukin, Dana J. , Gao, Youran, Bohm, Matthew , Shmidt, Eugenia , Meserve, Joseph , Winters, Adam C. , Chablaney, Shreya , Yang, Jiao, Huang, Zhongwen, Boland, Brigid S. , Shashi, Preeti , Weiss, Aaron , Varma, Sashidhar, Fischer, Monika , Sultan, Keith , Shen, Bo , Kane, Sunanda V. , Loftus, Edward V. , Sandborn, William J. , Lasch, Karen, Dulai, Parambir S. , Aniwan, Satimai , Loftus, Edward V , Chang, Shannon, Swaminath, Arun C. , Gupta, Nitin Kumar , Faleck, David M. , Weiss, Aaron, Hudesman, David , Sands, Bruce E , Colombel, Jean‐Frédéric , Siegel, Corey A

Mayo Clinic

Inflammatory Bowel Diseases | May 3, 2019 | Volume: 25 | Issue: 11 | Pages: 1854-1861

10.1093/ibd/izz071 | PMID 31050734 Get It

Abstract Background Vedolizumab effectiveness estimates immediately after Food and Drug Administration (FDA) approval for ulcerative colitis (UC) and Crohn’s disease (CD) are limited by use in refractory populations. We aimed to compare treatment patterns and outcomes of vedolizumab in 2 time frames after FDA approval. Methods We used 2 data sets for time trend analysis, an academic multicenter vedolizumab consortium (VICTORY) and the Truven MarketScan database, and 2 time periods, May 2014–June 2015 (Era 1) and July 2015–June 2017 (Era 2). VICTORY cumulative 12-month clinical remission, corticosteroid-free remission, and mucosal healing rates, and Truven 12-month hospitalization and surgery rates, were compared between Eras 1 and 2 using time-to-event analyses. Results A total of 3661 vedolizumab-treated patients were included (n = 1087 VICTORY, n = 2574 Truven). In both cohorts, CD and UC patients treated during Era 2 were more likely to be biologic naïve. Compared with Era 1, Era 2 CD patients in the VICTORY consortium had higher rates of clinical remission (31% vs 40%, P = 0.03) and mucosal healing (42% vs 58%, P < 0.01). These trends were not observed for UC. In the Truven database, UC patients treated during Era 2 had lower rates of inflammatory bowel disease–related hospitalization (22.4% vs 9.6%, P < 0.001) and surgery (17.2% vs 9.4%, P = 0.008), which was not observed for CD. Conclusion Since FDA approval, remission and mucosal healing rates have increased for vedolizumab-treated CD patients, and vedolizumab-treated UC patients have had fewer hospitalizations and surgeries. This is likely due to differences between patient populations treated immediately after drug approval and those treated later.
Localizing Epileptogenic Regions Using High-Frequency Oscillations and Machine Learning
Weiss, Shennan A. , Waldman, Zachary, Raimondo, Federico , Bragin, Anatol , Engel, Jerome , Staba, Richard J. , Sperling, Michael R. , Sperling, Michael R , Weiss, Shennan A , Slezak, Diego Fernández , Donmez, Mustafa, Worrell, Gregory A.

Mayo Clinic

Biomarkers in Medicine | May 2, 2019 | Volume: 13 | Issue: 5 | Pages: 409-418

10.2217/bmm-2018-0335 | PMID 31044598 Get It

Cardiac and renal biomarker responses in a phase 1/2 study of NEOD001 in patients with AL amyloidosis and persistent organ dysfunction.
Landau, Heather , Comenzo, Ray, Weiss, Brendan M. , Zonder, Jeffrey A. , Walling, Jackie , Kinney, Gene G. , Koller, Marty, Liedtke, Michaela , Gertz, Morie A. , Seldin, David C.

Mayo Clinic

Journal of Clinical Oncology | April 22, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 8514-8514

10.1200/jco.2015.33.15_suppl.8514 Get It

The VITAL study: A randomized, double-blind, placebo-controlled, global, phase III study of NEOD001 in patients with AL amyloidosis and cardiac dysfunction.
Liedtke, Michaela , Landau, Heather , Comenzo, Ray, Weiss, Brendan M. , Zonder, Jeffrey A. , Walling, Jackie , Kinney, Gene G. , Koller, Marty, Merlini, Giampaolo , Seldin, David C. , Gertz, Morie A.

Mayo Clinic

Journal of Clinical Oncology | April 19, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 8614-8614

10.1200/jco.2015.33.15_suppl.8614 Get It

The historical context and scientific legacy of John O. Holloszy
Hagberg, James M. , Coyle, Edward F. , Baldwin, Kenneth M., Cartee, Gregory D. , Fontana, Luigi , Kirwan, John P. , Weiss, Edward P., Kirwan, John P , Joyner, Michael J. , Seals, Douglas R.

Mayo Clinic

Journal of Applied Physiology | February 7, 2019 | Volume: 127 | Issue: 2 | Pages: 277-305

10.1152/japplphysiol.00669.2018 | PMID 30730811 Get It

John O. Holloszy, as perhaps the world’s preeminent exercise biochemist/physiologist, published >400 papers over his 50+ year career, and they have been cited >41,000 times. In 1965 Holloszy showed for the first time that exercise training in rodents resulted in a doubling of skeletal muscle mitochondria, ushering in a very active era of skeletal muscle plasticity research. He subsequently went on to describe the consequences of and the mechanisms underlying these adaptations. Holloszy was first to show that muscle contractions increase muscle glucose transport independent of insulin, and he studied the mechanisms underlying this response throughout his career. He published important papers assessing the impact of training on glucose and insulin metabolism in healthy and diseased humans. Holloszy was at the forefront of rodent studies of caloric restriction and longevity in the 1980s, following these studies with important cross-sectional and longitudinal caloric restriction studies in humans. Holloszy was influential in the discipline of cardiovascular physiology, showing that older healthy and diseased populations could still elicit beneficial cardiovascular adaptations with exercise training. Holloszy and his group made important contributions to exercise physiology on the effects of training on numerous metabolic, hormonal, and cardiovascular adaptations. Holloszy’s outstanding productivity was made possible by his mentoring of ~100 postdoctoral fellows and substantial NIH grant funding over his entire career. Many of these fellows have also played critical roles in the exercise physiology/biochemistry discipline. Thus it is clear that exercise biochemistry and physiology will be influenced by John Holloszy for numerous years to come.
E1A06: A phase III trial comparing melphalan, prednisone, and thalidomide (MPT) versus melphalan, prednisone, and lenalidomide (MPR) in newly diagnosed multiple myeloma (MM).
Stewart, A. Keith, Jacobus, Susanna , Weiss, Matthias , Chanan‐Khan, Asher , Fonseca, Rafaël , Callander, Natalie S. , Rajkumar, S. Vincent

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 8511-8511

10.1200/jco.2014.32.15_suppl.8511 Get It

Immunologic activity of an activating anti-CD27 antibody (CDX-1127) in patients (pts) with solid tumors.
Infante, Jeffrey R., Burris, Howard A. , Ansell, Stephen M. , Villalobos, Víctor M. , Šikić, Branimir I. , Northfelt, Donald W. , Pilja, Lana, Hawthorne, Thomas, Davis, Thomas A. , Keler, Tibor , Nemunaitis, John , Weiss, Geoffrey R. , Taylor, Matthew H. , Carson, William E. , Yellin, Michael , Bullock, Timothy N J

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 3027-3027

10.1200/jco.2014.32.15_suppl.3027 Get It